|
|
ASH 2011: Dr. Vij - Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA
|
|
|
button next to the volume control in the
lower right hand corner.
print
related articles